Century Therapeutics Q4 2025 Earnings Report

Century Therapeutics EPS Results

• Actual EPS: -$0.25
• Consensus EPS: -$0.29
• Beat/Miss: Beat by +$0.04
• One Year Ago EPS: N/A

Century Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: ($0.08) million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Century Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/12/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, March 12, 2026
• Conference Call Time: 7:00AM ET

Century Therapeutics (NASDAQ:IPSC) is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. Early-stage programs include iPSC-derived NK cell candidates engineered for enhanced tumor targeting and persistence, alongside T cell programs incorporating novel receptor constructs. Century has established strategic collaborations with leading pharmaceutical partners to advance preclinical research and prepare select programs for clinical evaluation.

Founded in 2019 as a spin-out from the Wistar Institute and the University of Pennsylvania, Century Therapeutics is headquartered in Philadelphia. Since its inception, the company has built multidisciplinary teams across research, manufacturing and regulatory affairs. Century’s leadership brings experience from established biopharmaceutical companies and academic institutions, supporting its goal of delivering transformative cell therapies to patients worldwide.